1133 related articles for article (PubMed ID: 28550091)
21. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
Barish ME; Weng L; Awabdeh D; Zhai Y; Starr R; D'Apuzzo M; Rockne RC; Li H; Badie B; Forman SJ; Brown CE
Neoplasia; 2022 Aug; 30():100801. PubMed ID: 35550513
[TBL] [Abstract][Full Text] [Related]
22. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
23. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
24. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
25. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
26. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
[TBL] [Abstract][Full Text] [Related]
27. CAR T-Cell Therapies in Glioblastoma: A First Look.
Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD; June CH
Clin Cancer Res; 2018 Feb; 24(3):535-540. PubMed ID: 29158268
[TBL] [Abstract][Full Text] [Related]
28. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
29. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
[TBL] [Abstract][Full Text] [Related]
30. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
Shum T; Omer B; Tashiro H; Kruse RL; Wagner DL; Parikh K; Yi Z; Sauer T; Liu D; Parihar R; Castillo P; Liu H; Brenner MK; Metelitsa LS; Gottschalk S; Rooney CM
Cancer Discov; 2017 Nov; 7(11):1238-1247. PubMed ID: 28830878
[TBL] [Abstract][Full Text] [Related]
31. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
32. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
33. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
[TBL] [Abstract][Full Text] [Related]
34. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
35. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
36. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
37. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
39. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
40. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]